Eli Lilly and (NYSE:LLY) issued an update on its FY18 earnings guidance on Wednesday morning. The company provided EPS guidance of $4.81-4.91 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.67. The company issued revenue guidance of $23.0-23.5 billion, compared to the consensus revenue estimate of $23.20 billion.

Eli Lilly and (NYSE:LLY) opened at $87.00 on Wednesday. Eli Lilly and has a 12 month low of $74.00 and a 12 month high of $89.09. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. The stock has a market cap of $96,455.93, a price-to-earnings ratio of 40.80, a P/E/G ratio of 1.70 and a beta of 0.35.

Eli Lilly and (NYSE:LLY) last posted its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. During the same period last year, the business posted $0.95 EPS. Eli Lilly and’s revenue was up 7.0% compared to the same quarter last year. equities analysts anticipate that Eli Lilly and will post 4.22 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be paid a $0.5625 dividend. The ex-dividend date is Wednesday, February 14th. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a yield of 2.59%. Eli Lilly and’s dividend payout ratio (DPR) is presently 98.58%.

Several analysts have issued reports on LLY shares. Credit Suisse Group lowered shares of Eli Lilly and from an outperform rating to a neutral rating and raised their price target for the stock from $84.23 to $88.00 in a research report on Tuesday, October 10th. Zacks Investment Research upgraded shares of Eli Lilly and from a hold rating to a buy rating and set a $95.00 price target on the stock in a research report on Thursday, October 26th. BMO Capital Markets set a $73.00 price target on shares of Eli Lilly and and gave the stock a sell rating in a research report on Wednesday, November 1st. Morgan Stanley raised their price target on shares of Eli Lilly and from $86.00 to $90.00 and gave the stock an equal weight rating in a research report on Tuesday, November 21st. Finally, Berenberg Bank restated a buy rating and issued a $98.00 price target on shares of Eli Lilly and in a research report on Thursday, October 26th. Four analysts have rated the stock with a sell rating, six have given a hold rating and nine have issued a buy rating to the company. Eli Lilly and presently has a consensus rating of Hold and an average target price of $92.41.

In related news, major shareholder Lilly Endowment Inc sold 200,000 shares of Eli Lilly and stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the completion of the transaction, the insider now directly owns 123,084,104 shares of the company’s stock, valued at approximately $10,856,017,972.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Susan Mahony sold 36,585 shares of Eli Lilly and stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the transaction, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at $4,729,989.30. The disclosure for this sale can be found here. Insiders have sold a total of 251,088 shares of company stock valued at $22,041,236 over the last ninety days. 0.20% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: This report was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://theolympiareport.com/2018/01/31/eli-lilly-and-lly-issues-fy18-earnings-guidance.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.